No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Multiple myeloma remains a significant challenge in hematologic oncology, with limited curative options for many patients.
• High-risk cytogenetics and relapse after B-cell maturation antigen (BCMA)-targeting therapies represent critical unmet needs.
• Existing treatments often fail to achieve durable remissions in advanced or relapsed multiple myeloma.

Purpose of the Study:

• To introduce a novel Chimeric Antigen Receptor (CAR) engineered Natural Killer (NK) cell therapy.
• To evaluate the potential of a CD27 CAR-IL15 NK cell therapy targeting CD70 for multiple myeloma treatment.
• To address the urgent need for new therapeutic strategies in relapsed/refractory multiple myeloma.

Main Methods:

• Development of a novel CAR construct incorporating IL-15 signaling.
• Engineering of NK cells to express the CD27 CAR targeting the CD70 antigen.
• Preclinical evaluation of the CD70-directed CAR-IL15 NK cell therapy in multiple myeloma models.

Main Results:

• The novel CD27 CAR-IL15 NK cell therapy demonstrates potent anti-myeloma activity.
• Targeting CD70 on multiple myeloma cells with engineered NK cells shows efficacy.
• This approach offers a potential new avenue for patients resistant to current therapies.

Conclusions:

• CD70-targeting CD27 CAR-IL15 NK cells represent a promising novel therapeutic strategy.
• This innovative cell therapy may overcome limitations of current BCMA-targeted treatments.
• Further investigation is warranted to explore the clinical utility of this approach in multiple myeloma.